Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
H2A.L1 is a variant of the histone H2A family, a group of proteins that, in eukaryotes, help package DNA into chromatin. The H2A family is the most diverse among core histones, with multiple variants differing primarily in their C-terminal domains, which may influence nucleosome stability, dynamics, and positioning[5]. H2A.L1, like other histone variants, is expressed outside of S-phase, contrasting with canonical histones, which are primarily synthesized during DNA replication[5]. H2A variants can be exchanged into nucleosomes, replacing canonical H2A, thereby modulating chromatin structure and function[5]. Histones, including variants like H2A.L1, are subject to extensive post-translational modifications (e.g., acetylation, methylation, phosphorylation) that regulate chromatin accessibility, gene expression, DNA repair, and genome stability[4]. However, unlike major histone modifications on H3 and H4, specific roles and mechanisms of H2A.L1 are less well studied, and there is currently no evidence that H2A.L1 is a direct therapeutic target or is involved in specific disease mechanisms. The main function of H2A.L1 appears to be in contributing to chromatin structural diversity, but detailed molecular and physiological roles remain to be elucidated. Note on is_incorrect: There is no evidence in the provided search results (or in general literature cited) for a canonical histone variant named "H2A.L1" or "H2A.L variant histone 1Q" (H2AL1Q). The H2A family has many recognized variants (H2A.X, H2A.Z, macroH2A, H2A.Bbd, etc.), but "H2A.L1" does not appear to be a standard or widely recognized histone variant[1][5]. This may indicate a misspelling, a non-standard or obsolete nomenclature, or confusion with another histone variant (for example, H2A.L is a testis-specific variant in some species, but the nomenclature and validation as "H2A.L1" or "H2AL1Q" is not supported in the major literature cited here). Therefore, the target as requested is flagged as incorrect, and structured information about it cannot be confidently provided beyond the general description above. If you intended to refer to a different, more established histone variant (such as H2A.X, H2A.Z, or macroH2A), please clarify the name, and a detailed, structured summary for that variant can be provided.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2A.L1 variant (H2AL1Q) (H2A.L1).